BELLEROPHON THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)

Published: 2021-10-06 09:00:11 ET BLPH

Item 5.02. Departure of Directors or Certain Officers; Election of Directs; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(c)On September 30, 2021, the Board of Directors of Bellerophon Therapeutics, Inc. (the "Company") appointed Nicholas Laccona, the Company's Controller, to serve as the Principal Financial Officer and Principal Accounting Officer of the Company, effective as of September 30, 2021. Mr. Laccona has served as the Controller of the Company since August 2020. Prior to joining the Company, Mr. Laccona served as Senior Manager, Audit at KPMG LLP from December 2014 to August 2020. Prior to KPMG LLP, Mr. Laccona was an auditor with Sobel & Co., LLC. Mr. Laccona holds a Bachelor's degree from the University of Maryland, College Park and is a Certified Public Accountant.

Mr. Laccona did not receive additional compensation upon his appointment as Principal Financial Officer and Principal Accounting Officer of the Company.

Mr. Laccona has no family relationships with any of the executive officers or directors of the Company. There are no arrangements or understandings between Mr. Laccona and any other person pursuant to which she was elected as an officer of the Company.